Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Minimal Diagnostic Value of Karyotyping for Suspected Myelodysplastic Syndrome in the Absence of Bone Marrow Dysplasia

Mark Trinder, Helene Bruyere, Eric McGinnis

Blood (2022) 140 (Supplement 1): 12325–12326.

https://doi.org/10.1182/blood-2022-158813

Published: 2022

Journal Articles

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Elysha Vanderveer, MD BSc, Steven J.T. Huang, BMLSc, Helene Bruyere, MD FCCMG, Tanya Gillan, PhD FCCMG, Charles H. Li, MDFRCPC, Khaled Ramadan, MBBCH, MRCP, FRCPath, Diego Villa, MD MPH, David W. Scott, MBChB, PhD, Kerry J Savage, BSc, MD MSc, Joseph M Connors, MD, Laurie H Sehn, MD, Cynthia L Toze, MD FRCPC, Alina S Gerrie, MD MPH

Blood (2019) 134 (Supplement_1): 4300.

https://doi.org/10.1182/blood-2019-125189

Published: 2019

Journal Articles

Unsuccessful Cytogenetics and Outcomes in Acute Leukemia

Lauren Lee, MD, Helene Bruyere, MD, Michael J Barnett, BM, Raewyn Broady, MBChB, Donna L. Forrest, MD, Alina S. Gerrie, MD MPH, Donna E. Hogge, MD PhD, Stephen H. Nantel, MD, Sujaatha Narayanan, MBBS, Maryse Power, MD, David Sanford, MD, Kevin Song, MD, Heather J. Sutherland, MD PhD, Cynthia L Toze, MD, Jennifer White, MD, Yasser Abou Mourad, MD

Blood (2018) 132 (Supplement 1): 2673.

https://doi.org/10.1182/blood-2018-99-110470

Published: 2018

Journal Articles

Clinical Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion in British Columbia (BC), Canada: Results of a Population-Based Cohort

Jennifer Goy, MD MSc, Tanya L. Gillan, PhD FCCMG, Huang J.T. Steven, Helene Bruyere, MD FCCMG, Monica Anne Hrynchak, MD FRCPC, Aly Karsan, MD, Khaled Ramadan, MB, MRCP, MRCPath, Adam C. Smith, PhD FCCMG, FACMG, Cynthia L. Toze, MD FRCP(C), Alina S. Gerrie, MD MPH

Blood (2014) 124 (21): 2648.

https://doi.org/10.1182/blood.V124.21.2648.2648

Published: 2014

Journal Articles

Comparison of Outcomes in Chronic Lymphocytic Leukemia (CLL) with the Addition of Rituximab to Initial Treatment: A Comparative Effectiveness Analysis in the Province of British Columbia (BC), Canada

Lauren J. Lee, MD, Alina S. Gerrie, MD FRCPC, Helene Bruyere, MD FCCMG, Tanya L. Gillan, PhD FCCMG, Stephen J.T. Huang, BMLSc, Cynthia L. Toze, MD FRCPC, Khaled M. Ramadan, MBBCh, MRCPI, FRCPath, FRCP, FRCPC

Blood (2014) 124 (21): 3344.

https://doi.org/10.1182/blood.V124.21.3344.3344

Published: 2014

Journal Articles

MYC fireworks

Hélène Bruyère, Tanya Gillan

Blood (2014) 123 (1): 13.

https://doi.org/10.1182/blood-2013-09-525865

Published: 2014

Journal Articles

Clonal Evolution Predicts Poor Prognosis in Chronic Lymphocytic Leukaemia and Is Possibly a Worse Prognostic Factor Than 17p Deletion: A Population Based Cohort study of FISH Testing in British Columbia, Canada

Krystal Bergin, MBBS, Alina S. Gerrie, MD, FRCPC, Steven J.T. Huang, BMLSc, Khaled M Ramadan, MBBCH, MRCPI, FRCPath, FRCP, FRCPC, Aly Karsan, MD, Monica Anne Hrynchak, MD, FRCP(C), Chinmay B. Dalal, MD, Helene Bruyere, MD, FCCMG, Adam C. Smith, PhD, FCCMG, FACMG, Cynthia L. Toze, MD, MHSc, FRCPC, Tanya L. Gillan, PhD, FCCMG

Blood (2012) 120 (21): 1401.

https://doi.org/10.1182/blood.V120.21.1401.1401

Published: 2012

Journal Articles

Comprehensive Assessment of Clinical Outcomes for CLL Patients with Trisomy 12 (+12): Results of a Population-Based Analysis of 822 CLL Patients in British Columbia (BC), Canada

Alina S. Gerrie, MD, FRCPC, MPH, Steven J.T. Huang, BMLSc, Helene Bruyere, MD, FCCMG, Chinmay B. Dalal, MD, Monica Anne Hrynchak, MD, FRCP(C), Aly Karsan, MD, Khaled M Ramadan, MBBCH, MRCPI, FRCPath, FRCP, FRCPC, Adam C. Smith, PhD, FCCMG, FACMG, Tanya L. Gillan, PhD, FCCMG, Cynthia L. Toze, MD, FRCP(C)

Blood (2012) 120 (21): 3897.

https://doi.org/10.1182/blood.V120.21.3897.3897

Published: 2012

Journal Articles

T Cells of Patients with Myelodysplastic Syndrome Are Frequently Derived From the Malignant Clone

Suzanne Vercauteren, MD, PhD, Daniel T. Starczynowski, PhD, Sandy Sung, Kelly McNeil, Chris Salski, Clara-Lynn Jensen, Helene Bruyere, MD, FCCMG, Wan Lam, Aly Karsan, MD, FRCPC

Blood (2011) 118 (21): 2808.

https://doi.org/10.1182/blood.V118.21.2808.2808

Published: 2011

Journal Articles

Impact of Immunoglobulin Heavy Chain (IGH) Translocations In Chronic Lymphocytic Leukemia (CLL): Negative Effect on Patients with Isolated Deletion 13q Abnormality

Alina S. Gerrie, MD, FRCPC, Tanya L. Gillan, PhD, FCCMG, Helene Bruyere, MD, FCCMG, Mary Joyce Chan, BMLSc, Chinmay B. Dalal, MD, Cynthia L. Toze, MD, FRCPC

Blood (2010) 116 (21): 2434.

https://doi.org/10.1182/blood.V116.21.2434.2434

Published: 2010

Journal Articles

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

Donna Reece, Kevin W. Song, Tommy Fu, Birgitte Roland, Hong Chang, Douglas E. Horsman, Adnan Mansoor, Christine Chen, Esther Masih-Khan, Young Trieu, Helene Bruyere, Douglas A. Stewart, Nizar J. Bahlis

Blood (2009) 114 (3): 522–525.

https://doi.org/10.1182/blood-2008-12-193458

Published: 2009

Journal Articles

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Nizar J Bahlis, MD, Kevin W. Song, Tommy Fu, Birgitte J Roland, MD, FCCMG, DABMG, Hong Chang, Doug Horsman, MD, PhD, Adnan Mansoor, MD, FRCPC, Christine Chen, MD, Esther Masih- Khan, Young Trieu, MSc, Helene Bruyere, MD, Douglas A. Stewart, MD, FRCPC, Donna E. Reece, MD

Blood (2008) 112 (11): 1731.

https://doi.org/10.1182/blood.V112.11.1731.1731

Published: 2008

Journal Articles

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

Nizar J. Bahlis, MD, Kevin Song, MD, Young Trieu, BS, MS, Birgitte Roland, MD, Esther Masih-Khan, PhD, Hong Chang, MD, Helene Bruyere, MD, Adnan Mansoor, MD, Douglas Horsman, MD, Michael Eliasziw, PhD, Douglas Stewart, MD, Donna Reece, MD

Blood (2007) 110 (11): 3597.

https://doi.org/10.1182/blood.V110.11.3597.3597

Published: 2007

Journal Articles

Philadelphia-Negative Clonal Hematopoiesis Following Imatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Yulia Lin, MD, Helene Bruyere, MD, Douglas E. Horsman, MD, Michael J. Barnett, BM, Donna E. Hogge, MD, PhD, Thomas J. Nevill, MD, Stephen H. Nantel, MD, Heather J. Sutherland, MD, PhD, Cynthia L. Toze, MD, John D. Shepherd, MD, Julye C. Lavoie, MD, Kevin W. Song, MD, Clayton A. Smith, MD, Donna L. Forrest, MD

Blood (2004) 104 (11): 4696.

https://doi.org/10.1182/blood.V104.11.4696.4696

Published: 2004

NARROW

Minimal Diagnostic Value of Karyotyping for Suspected Myelodysplastic Syndrome in the Absence of Bone Marrow Dysplasia

Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC)

Unsuccessful Cytogenetics and Outcomes in Acute Leukemia

Clinical Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion in British Columbia (BC), Canada: Results of a Population-Based Cohort

Comparison of Outcomes in Chronic Lymphocytic Leukemia (CLL) with the Addition of Rituximab to Initial Treatment: A Comparative Effectiveness Analysis in the Province of British Columbia (BC), Canada

MYC fireworks

Clonal Evolution Predicts Poor Prognosis in Chronic Lymphocytic Leukaemia and Is Possibly a Worse Prognostic Factor Than 17p Deletion: A Population Based Cohort study of FISH Testing in British Columbia, Canada

Comprehensive Assessment of Clinical Outcomes for CLL Patients with Trisomy 12 (+12): Results of a Population-Based Analysis of 822 CLL Patients in British Columbia (BC), Canada

T Cells of Patients with Myelodysplastic Syndrome Are Frequently Derived From the Malignant Clone

Impact of Immunoglobulin Heavy Chain (IGH) Translocations In Chronic Lymphocytic Leukemia (CLL): Negative Effect on Patients with Isolated Deletion 13q Abnormality

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

Philadelphia-Negative Clonal Hematopoiesis Following Imatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only